Association study between clinical response to rizatriptan and some candidate genes

被引：22

作者：

Asuni, Carlo

Cherchi, Alessandra

Congiu, Donatella

Piccardi, Maria P.

Del Zompo, Maria

Stochino, Maria E.

机构：

[1] Section of Clinical Pharmacology, Department of Neurosciences B.B. Brodie, University of Galiari, I-09124 Cagliari

来源：

JOURNAL OF HEADACHE AND PAIN | 2007年 / 8卷 / 03期

关键词：

migraine; triptans; pharmacogenetics; dopamine; DRD2;

D O I：

10.1007/s10194-007-0388-5

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The aim of this study was to test genetic differences in the clinical response to rizatriptan in patients affected by migraine without aura. These genetic differences could be explained by various genes, the HTR1B, encoding the 5-HT1 receptor subtype, MAO-A gene that encodes the monoamino-oxidase, the main metabolic enzyme of this triptan, SLC6A4 (gene encoding the serotonin transporter) and DRD2 (gene encoding the D-2 receptor), both involved in the pathogenesis of migraine. Fifty unrelated patients affected by migraine without aura (IHS) were included. Patients were divided into two groups (responders and non-responders) according to clinical response. Thirty-one out of fifty patients responded to rizatriptan. A significant difference among the two groups was observed in both allele (p=0.02) and genotype distribution (p=0.03) of DRD2/NcoI. The significant association with the DRD2/NcoI polymorphism in responders suggested that the DRD2/NcoI C allele may be considered a susceptibility factor heralding a good response to rizatriptan.

引用

页码：185 / 189

页数：5

共 20 条

[1]

Visser W.H., Burggraaf J., Muller L.M., Et al., Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response, Clin Pharmacol Ther, 60, pp. 452-460, (1996)

[2]

Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J., Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials, Lancet, 358, pp. 1668-1675, (2001)

[3]

Waeber C., Moskowitz M.A., Therapeutic implications of central and peripheral neurologic mechanisms in migraine, Neurology, 61, SUPPL. 4, (2003)

[4]

Maassen VanDenBrink A., Van Den Broek R.W.M., De Vries R., Et al., Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels, Neurology, 55, pp. 1524-1530, (2000)

[5]

Peroutka S.J., Dopamine and migraine, Neurology, 49, pp. 650-656, (1997)

[6]

Peroutka S.J., Wilholt T., Jones K., Clinical susceptibility in migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles, Neurology, 49, pp. 201-206, (1997)

[7]

Del Zompo M., Cherchi A., Palmas M.A., Et al., Association between dopamine receptor genes and migraine without aura in a Sardinian sample, Neurology, 51, pp. 781-786, (1998)

[8]

Mathew N.T., Kailasam J., Gentry P., Chernyshev O., Treatment on nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: A comparative open trials, Headache, 40, pp. 464-465, (2000)

[9]

Sarkar G., Kapelner S., Grandy D.K., Et al., Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor, Genomics, 11, pp. 8-14, (1991)

[10]

Arinami T., Gao M., Hamaguchi H., Toru M., A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associate with schizophrenia, Hum Mol Genet, 6, pp. 577-582, (1997)

← 1 2 →